1. Sweden Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Stille AB

Stille AB

SSTO:STIL
268.00
SEK
+2.50
(+0.94%)
9.10EPS
28.47P/E
2.33BMarket Cap
Oct 23Next Earn
Stille AB
STO:STIL
(Nasdaq Stockholm)

Recent

price

268.00

P/E

ratio

28.47

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
SEK
17.28
18.62
18.24
18.46
18.53
17.26
19.97
25.22
28.16
32.46
29.48
37.31
49.14
58.77
63.45
63.18
74.12
Revenue per Share
0.72
-0.22
-0.4
0.68
0.43
2.17
3.48
3.02
4.26
4.74
1.71
3.21
5.45
5.31
6.48
6.2
9.1
Basic EPS, GAAP
0.11
-0.56
-0.81
-0.51
-0.87
1.93
3.71
3.38
1.8
3.72
-0.6
-2.34
4.77
4.86
6.52
1.72
5.79
Free Cash Flow per Basic Share
- -
- -
- -
- -
1.1
- -
0.8
1
1.2
1.45
- -
1.64
1
1.8
- -
- -
- -
Dividend per Share
8.5
8.32
7.88
8.57
7.96
10.15
12.91
14.83
18.03
21.34
23
29.54
37.86
126.11
77.84
78.87
86.17
Book Value per Share
5.64
5.07
2.76
6.52
6.15
8.65
11.75
13.29
16.2
18.41
15.72
3.24
8.66
95.06
21.75
17.87
23.49
Tangible Book Value per Share
5
5
5
5
4
5
5
5
5
5
5
5
5
5
9
9
9
Basic Weighted Avg Shares
83
90
88
89
81
83
96
122
136
157
143
187
246
295
570
568
666
Sales/Revenue/Turnover
-3.07
-1.13
-0.87
3.34
1.4
12.21
16.89
17.26
17.86
17.65
11.32
12.79
13.24
16.45
20.16
14.66
15.39
Operating Margin (%)
1
1
1
3
3
3
3
3
4
5
4
7
10
14
45
36
- -
Depreciation Expense
3
-1
-2
3
2
10
17
15
21
23
8
16
27
27
58
56
82
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
21.68
19.63
20.48
23.53
21.93
16.7
15.64
15.85
26.11
13.58
Effective Tax Rate (%)
4.18
-1.17
-2.18
3.69
2.32
12.57
17.43
11.97
15.13
14.6
5.8
8.6
11.09
9.04
10.21
9.81
12.27
Profit Margin (%)
18
15
4
18
19
34
49
60
76
87
74
76
94
509
277
292
333
Working Capital
1
1
1
1
2
2
1
1
- -
22
22
68
58
38
36
108
- -
LT Debt
41
40
38
41
38
49
62
72
87
103
111
148
190
632
699
709
774
Total Equity
- -
- -
- -
6.86
2.7
21.54
27.96
22.2
25.09
20.17
8.13
8.54
11.01
7.93
8.07
6.69
12.24
Return on Invested Capital (%)
- -
- -
- -
8.09
4.66
22.33
28.99
22.2
25.73
21.76
6.71
9.48
11.94
7.36
8.57
7.38
13.11
Return on Capital (%)
8.8
-2.59
-4.9
8.28
4.74
24.01
30.17
21.78
25.9
24.07
7.73
12.42
16.17
6.48
8.74
7.91
11.29
Return on Common Equity (%)

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
16
- -
- -
LT Borrowings
66
- -
- -
LT Finance Leases
42
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
9
9
9
Market Capitalization
1,761
1,968
2,327

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
408
442
465
Cash, Cash Equivalents & STI
119
138
149
Accounts Receivable, Net
88
97
99
Inventories
182
186
190
Total Current Liabilities
116
126
133
Payables & Accruals
- -
- -
- -
ST Debt
16
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
39.64%
61.31%
1.33%
Free Cash Flow
9.82%
14.39%
-73.61%
Net Income, GAAP
31.12%
55.19%
-4.31%
Sales/Revenue/Turnover
23.51%
35.08%
-0.41%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
140
143
128
161
570
2025
129
125
- -
175
568
2026
179
187
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.37
2.03
1.53
1.81
6.48
2025
1.63
1.11
- -
3.37
6.2
2026
2.33
2.29
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Stille AB (STIL.ST) develops, manufactures, and markets premium surgical instruments and C-arm tables for specialist surgeons worldwide. Founded in 1841 and headquartered in Torshälla, Sweden, the company operates through two main segments: Surgical Instruments, encompassing hand-forged reusable tools such as scissors, forceps, retractors, skin hooks, and SuperCut scissors for open surgery in cardiovascular, plastic, microsurgical, neuro, spine, thoracic, and general specialties; and Surgical Tables, including advanced fluoroscopy models like imagiQ2 and Medstone optimized for minimally invasive procedures with C-arms, featuring True Free Float technology, enhanced translucency for superior imaging, and partnerships with GE Healthcare, Ziehm Imaging, Philips, and Siemens Healthineers. Complementary services include instrument care education, repair, maintenance, inspection, and a 30-year warranty on instruments. Stille maintains direct operations in Sweden, Germany, Switzerland, the United States, the United Kingdom, the UAE, and Malaysia, serving hospitals, clinics, and surgeons through distributors and direct sales channels, with a focus on high-margin niche segments enabling premium pricing and long-term customer relationships built on quality and switching costs. In recent developments, Stille completed the acquisition of Fehling Instruments in early 2024 for EUR 36 million, broadening its surgical instrument portfolio in neuro, spine, and cardiac surgery, enhancing R&D, and expanding global direct presence; in July 2025, it agreed to acquire Surgical Holdings for GBP 7.7 million, strengthening UK market access with direct sales, repair services for instruments, endoscopes, and orthopaedic tools, and complementary offerings in general surgery and orthopaedics, with closing expected in Q3 2025. These moves align with Stille's consolidation strategy in the fragmented premium medtech market, driving revenue growth to SEK 554 million (TTM) and adjusted EBITDA expansion.